Patient's anastrozole compliance to therapy (PACT) program: Baseline data and patient characteristics from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer

Breast Care

Volumn 8, Issue 2, 2013, Pages 110-120

  Harbeck, Nadia ^a   Blettner, Maria ^b   Hadji, Peyman ^c   Jackisch, Christian ^d   Lück, Hans Joachim ^e   Windemuth Kieselbach, Christine ^f   Zaun, Silke ^g   Haidinger, Renate ^h   Schmitt, Doris ⁱ   Schulte, Hilde ^j   Nitz, Ulrike ^k,l   Kreienberg, Rolf ^m  

^a UNIVERSITY OF MUNICH   (Germany)

^b IMBEI   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d Klinikum Offenbach   (Germany)

^e Gynecologic Oncological Practice Hannover ^*  (Germany)

^f ALCEDIS GMBH   (Germany)

^g ASTRAZENECA   (United Kingdom)

^h Brustkrebs Deutschland eV   (Germany)

ⁱ PATH Foundation   (Germany)

^j Frauenselbsthilfe Nach Krebs EV   (Germany)

^k Niederrhein Breast Centre   (Germany)

^l Westdeutsches Brust Centrum   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

Aromatase inhibitors; Breast cancer; Breast conserving surgery; Compliance; Mastectomy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; HORMONE; HORMONE RECEPTOR; METHOTREXATE;

AGE; AGED; ARTICLE; BILATERAL CANCER; BODY MASS; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CONTROLLED STUDY; DIARRHEA; EARLY CANCER; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; NAUSEA; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCEPTION; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SLEEP DISORDER; VOMITING; ADJUVANT CHEMOTHERAPY; ADULT; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CLINICAL EVALUATION; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; GYNECOLOGIST; HORMONE SENSITIVITY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; ONCOLOGIST; PATIENT ATTITUDE; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84878495382     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000350777     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Kaatsch P, Spix C, Katalinic A, Hentschel S, Baras N, Barnes B, Bertz J, Dahm S, Haberland J, Kraywinkel K, Laudi A, Wolf U: Krebs in Deutschland 2007/2008. Gesundheitsberichterstattung des Bundes 2012. Berlin, Robert Koch-Institut, 2012.
3. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge S, Farrar WB, Forero A, Hermes Giordano S, Goldstein LJ, Gradishar W, Hayes D, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce L: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 3. 2012). Fort Washington, National Comprehensive Cancer Network, 2012.
4. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet 2011;378:771-784.
5. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-3796.
6. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-1747.
7. Aebi S, Davidson T, Gruber G, Cardoso F: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(suppl 6):vi12-vi24.
8. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC ( Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
9. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-1141.
10. Ward JH: Duration of adjuvant endocrine therapy of breast cancer: how much is enough? Curr Opin Obstet Gynecol 2010;22:51-55.
11. Ma AM, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, Rosenbaum-Smith SM, Tartter PI: Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008;196:500-504.
12. Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156-166.
13. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26: 556-562.
14. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-436.
15. Engel J, Nagel G, Breuer E, Meisner C, Albert US, Strelocke K, Sauer H, Katenkamp D, Mittermayer C, Heidemann E, Schulz KD, Kunath H, Lorenz W, Holzel D: Primary breast cancer therapy in six regions of Germany. Eur J Cancer 2002;38:578-585.
16. Luftner D, Henschke P, Pollmann D, Schildhauer S, Possinger K: Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany-final results of a survey among German breast cancer specialists. Onkologie 2005;28:639-644.
17. Bartlett JA: Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(suppl 1):S2-S10.
18. Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Camara A, Gaig C, Compta Y: Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. Eur J Neurol 2011;18:980-987.
19. Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R: Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 2000;89:561-573.
20. Sandison AJ, Gold DM, Wright P, Jones PA: Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg 1996;83:994-996.
21. Nattinger AB: Variation in the choice of breastconserving surgery or mastectomy: patient or physician decision making? J Clin Oncol 2005;23:5429-5431.
22. Nold RJ, Beamer RL, Helmer SD, McBoyle MF: Factors influencing a woman's choice to undergo breast-conserving surgery versus modified radical mastectomy. Am J Surg 2000;180:413-418.
23. Jassem J, Coombes RC, Ireland B, Hall E, Snowdon CF, Bliss JM: Approaches to postmastectomy radiotherapy (PMRT) in the intergroup exemestane study (IES). European Society for Radiotherapy and Oncology (ESTRO), 2006, Poster 680.
24. van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE: Association between age at diagnosis and diseasespecific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012;307:590-597.
25. van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW: Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg 2010;97:671-679.
26. Barni S, Venturini M, Molino A, Donadio M, Rizzoli S, Maiello E, Gori S: Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). Tumori 2011;97:559-563.
27. Wengstrom Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V: Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007;16:462-468.
28. Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Serin D, Gulcelik M, Deschamp V: The impact of educational materials on compliance and persistence with adjuvant aromatase inhibitors: 2 year follow-up and final results from the CARIATIDE study. Cancer Res 2011;71(suppl 24):P516-02.
29. Partridge AH, Avorn J, Wang PS, Winer EP: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-661.
30. Caro JJ, Speckman JL: Existing treatment strategies: does noncompliance make a difference? J Hypertens Suppl 1998;16:S31-S34.